Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
ACET 
Adicet Bio Inc (ACET)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/28/2025: ACET (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
7 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $5.6
1 Year Target Price $5.6
| 6 | Strong Buy |
| 0 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -40.26% | Avg. Invested days 30 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/28/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 63.16M USD | Price to earnings Ratio - | 1Y Target Price 5.6 |
Price to earnings Ratio - | 1Y Target Price 5.6 | ||
Volume (30-day avg) 7 | Beta 1.61 | 52 Weeks Range 0.45 - 1.63 | Updated Date 08/28/2025 |
52 Weeks Range 0.45 - 1.63 | Updated Date 08/28/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.3 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-07 | When - | Estimate -0.3114 | Actual -0.34 |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -36.52% | Return on Equity (TTM) -64.39% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value -46698445 | Price to Sales(TTM) 9.72 |
Enterprise Value -46698445 | Price to Sales(TTM) 9.72 | ||
Enterprise Value to Revenue 2.14 | Enterprise Value to EBITDA -1.21 | Shares Outstanding 83253800 | Shares Floating 61916668 |
Shares Outstanding 83253800 | Shares Floating 61916668 | ||
Percent Insiders 2.79 | Percent Institutions 61.26 |
Upturn AI SWOT
Adicet Bio Inc
Company Overview
History and Background
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies for cancer. Founded in 2016, the company has advanced its platform and pipeline through preclinical and clinical development.
Core Business Areas
- Gamma Delta T Cell Therapy: Adicet's core business revolves around developing off-the-shelf gamma delta T cell therapies for treating various types of cancer. Their focus is on enhancing the anti-tumor activity and persistence of these cells.
Leadership and Structure
Chen Schor serves as President and Chief Executive Officer. The company has a board of directors and a management team overseeing research, development, clinical operations, and corporate strategy.
Top Products and Market Share
Key Offerings
- ADI-001: ADI-001 is an allogeneic gamma delta T cell therapy targeting CD20 for the treatment of B-cell malignancies, currently in clinical trials. No current market share. Competitors include companies developing other cell therapies for B-cell lymphomas, such as Gilead (Kite) with Yescarta and Novartis with Kymriah.
- ADI-002: ADI-002 is an allogeneic gamma delta T cell therapy engineered with an IL-15 receptor fusion protein and a CD38-targeting CAR being developed for relapsed or refractory multiple myeloma. Competitors include companies developing cell therapies for multiple myeloma, such as Johnson & Johnson with Carvykti and Bristol Myers Squibb with Abecma.
Market Dynamics
Industry Overview
The cell therapy industry is rapidly evolving, with significant advancements in cancer treatment. Allogeneic cell therapies offer advantages in terms of scalability and accessibility compared to autologous therapies.
Positioning
Adicet Bio is positioned as a pioneer in the allogeneic gamma delta T cell therapy space. Their competitive advantage lies in their unique approach to engineering and enhancing gamma delta T cells for improved anti-tumor activity.
Total Addressable Market (TAM)
The total addressable market for cell therapies in oncology is estimated to be tens of billions of dollars. Adicet Bio is positioned to capture a portion of this market with its pipeline of allogeneic gamma delta T cell therapies targeting hematologic malignancies and solid tumors.
Upturn SWOT Analysis
Strengths
- Novel gamma delta T cell platform
- Experienced leadership team
- Strong preclinical and clinical data
- Potential for off-the-shelf cell therapies
- Focus on innovative engineering of gamma delta T cells
Weaknesses
- Clinical development stage (high risk)
- Dependence on successful clinical trial outcomes
- High cash burn rate
- Potential manufacturing challenges
- Competitive landscape in cell therapy
Opportunities
- Expanding pipeline to address additional cancers
- Partnerships with larger pharmaceutical companies
- Advancements in cell engineering technologies
- Potential for regulatory approvals
- Addressing unmet medical needs in cancer treatment
Threats
- Clinical trial failures
- Regulatory hurdles
- Competition from other cell therapy companies
- Manufacturing challenges
- Changes in the healthcare landscape
Competitors and Market Share
Key Competitors
- GILD
- BMY
- JNJ
Competitive Landscape
Adicet Bio competes in a rapidly evolving cell therapy landscape. Its gamma delta T cell platform offers a unique approach compared to CAR-T therapies. Success depends on demonstrating superior efficacy and safety in clinical trials.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by preclinical development, IND filing, and initiation of clinical trials.
Future Projections: Future growth is dependent on clinical trial success and potential regulatory approvals. Analyst estimates are not available without specific source data.
Recent Initiatives: Recent initiatives include advancing ADI-001 and ADI-002 in clinical trials, expanding the pipeline with new product candidates, and strengthening partnerships.
Summary
Adicet Bio is an early-stage biotechnology company with a promising gamma delta T cell therapy platform. Its success hinges on positive clinical trial outcomes. The company faces competition from established cell therapy players and needs to manage its cash burn effectively to advance its pipeline and partnerships. The company has potential but needs to get through high competition.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports (unavailable without subscription)
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. Market share data is estimated and may not be precise.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adicet Bio Inc
Exchange NASDAQ | Headquaters Boston, MA, United States | ||
IPO Launch date 2018-01-26 | CEO, President & Director Mr. Chen Schor BA, CPA, M.B.A. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 152 | Website https://www.adicetbio.com |
Full time employees 152 | Website https://www.adicetbio.com | ||
Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for autoimmune diseases and cancer in the United States. It offers gamma delta T cells engineered with chimeric antigen receptors (CARs) to facilitate durable activity in patients. The company's lead product candidate is ADI-001, an allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, which is in Phase I clinical trial for the potential treatment of autoimmune diseases and relapsed/refractory B-cell non-hodgkin's lymphoma. It also develops ADI-270, an armored gamma delta CAR T cell product candidate to treat multiple CD70+ solid tumor and hematological malignancies indications, with renal cell carcinoma. The company was founded in 2014 and is based in Boston, Massachusetts.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.